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Abstract
In the previous issue of the journal, Lin and coworkers present data
demonstrate that increased expression of estrogen receptor (ER)-β
in ER-α-positive breast cancer cells antagonizes a defined group of
ER-α/estrogen stimulated genes that are involved in cell cycle
regulation and DNA replication. Similar expression patterns for
these genes were found human ER-α positive breast tumors
expressing higher levels or ER-β, and this correlated with better
clinical outcome. The implications for these data, which suggest
that ER-β is a positive actor and diagnostic marker for therapeutic
outcome, are discussed.
The role of estrogen exposure as a risk factor for breast
cancer is well-documented [1] and appears to be reinforced
by the abrupt decline in new cases that correlates with
cessation of widespread standardized hormone replacement
therapy in post-menopausal women [2]. Estrogen exerts its
biologic actions, including broad changes in gene expression,
through nuclear proteins called estrogen receptors (ERs),
which now include two subtypes [3]: ER-α and ER-β.
Between 40% and 70% of all breast tumors express the first-
identified receptor, ER-α and the discovery of ER-β
highlighted potential for more complex tumor categories
[2-4]. The presence of ER-α protein has been a standard
criterion for instituting adjuvant therapy with antiestrogens
such as tamoxifen that antagonize ER function, or more
recently with aromatase inhibitors that prevent the synthesis
of endogenous estrogen [4,5]. However, many patients never
respond to such endocrine therapies, or they do not exhibit a
sustained response [6]. Additional tumor markers that might
inform therapeutic choices and increase the likelihood of
positive disease outcome are clearly invaluable. Over-
expression of some proteins, such as the signaling molecule
p130Cas or the epidermal growth factor receptor, has been
associated with therapeutic resistance to tamoxifen [7].
Conversely, expression of the progesterone receptor (PR), an
estrogen-stimulated gene, presumably identifies an estrogen-
sensitive cancer that might be inhibited by targeting the ER;
indeed, patients with ER-positive/PR-positive tumors are
more responsive to endocrine therapy than those with ER-
positive/PR-negative tumors [1,8].
The report by Lin and coworkers [9] presented in the
previous issue suggests that the presence of ER-β may also
be indicative of more successful therapeutic responses and
disease outcome in ER-positive tumors. In this case, however,
ER-β itself acts by antagonizing ER-α on a very specific
subset of estrogen-stimulated genes and actively prevents
ER-α stimulated cell growth. UsingT47D ER-positive breast
cancer cells that were engineered to inducibly over-express
ER-β Lin and coworkers identified a ‘signature’ of estrogen-
regulated genes, represented by six proteins involved in cell
cycle progression and eight implicated in DNA replication,
that are either attenuated or frankly antagonized by ER-β
over-expression, with or without estrogen. This was
accompanied by decreased cell replication. Most importantly,
the investigators examined expression of ER-β in ER-α-
positive primary breast tumors from a previously well
described cohort of patients who had been treated with
adjuvant tamoxifen therapy, and plotted gene expression
against disease outcome [10]. They found that ER-β mRNA
expression was negatively correlated with expression of 10
out of 12 of the tested signature genes in ER-α-positive
tumors, but not ER-α-negative ones. Furthermore, patients
with relatively higher levels of ER-β and lower expression of
the signature gene set mRNAs had significantly improved
outcomes, in terms of both disease-free and disease-specific
survival, compared with the group with lower levels of ER-β
and higher responsive gene set transcript levels.
ER-β was originally shown to have lower transcriptional
activity than ER-α for many model promoters or on specific
genes, and to antagonize ER-α actions on specific genes
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involved in cell cycle regulation in cell culture [2,11]. The
findings of previous attempts to identify any one mRNA or
protein identified in model systems as a single marker that
predicts disease-free survival have not been compelling. The
data presented by Lin and coworkers [9], however, suggest
that groups of ER-regulated genes working together in similar
pathways may bring about the desired clinical outcome, and
that these in vitro studies may be reflected in some clinical
outcomes. Furthermore, co-expression of ER-β with ER-α
appears to be critical to observinig the beneficial response,
although it is not currently clear whether both receptors are
expressed in exactly the same cells. These responses may
occur because the heterodimers formed between the two ER
subtypes may identify and modulate different genes than
either receptor alone [2,11]. Alternatively, the small number of
ER-β-positive-only tumors identified in the literature to date
might have arisen from different progenitor cells that do not
require estrogen for growth and that have high expression of
molecules that are associated with poorer disease outcome,
such as the HER family of growth factor receptors [12].
Thus, the addition of ER-β to tumor screening, in addition to
ER-α and PR, has the potential to provide interesting and
important information in assessing the best therapies and
disease prognosis. ER-β protein appears to be an active
protector in ER-α-positive breast cancer [8]. This has raised
the question of targeting ER subtypes preferentially with
newly available subtype-specific ligands [13]. Interestingly,
Lin and coworkers [9] found that genes encoding proteins
that are active in cell proliferation and cell survival were not
preferentially regulated by ER-β. However, some of these
genes can be stimulated by estrogen and antagonized by
some pure antiestrogens [14]. Thus, ligands or therapies that
antagonize such responses to estrogen but allow
antagonistic actions of ER-β may be most beneficial. As we
learn more about the basic biology and pathophysiology of
breast cancer, coupled with current elegant studies on
molecular actions of receptors and ligands, we have reason
to expect that both better diagnostics and therapies will be
developed.
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